 

 

Active Ingredient: Azilsartan kamedoxomil; chlorthalidone 

 

Dosage Form; Route: Tablet; oral 

 

Recommended Studies: Two studies 

 

1. Type of study: Fasting 


Design: Single-dose, two-way crossover in vivo 

Strength: Eq 40 mg medoxomil; 25 mg. 

Subjects: Healthy males and nonpregnant females, general population. 

Additional comments: For long half-life drugs like chlorthalidone, an AUC truncated at 
72 hours may be used in place of AUC0-t or AUC0-8. Refer to the amantadine 
hydrochloride tablet draft guidance for additional information regarding long half-life 
drugs 

Females should not be pregnant, and, if applicable, should practice abstention or 
contraception during the study 

______________________________________________________________________________ 

 

2. Type of study: Fed 


Design: Single-dose, two-way crossover in vivo 

Strength: Eq 40 mg medoxomil; 25 mg 

Subjects: Healthy males and nonpregnant females, general population 

Additional comments: Refer to the amantadine hydrochloride tablet draft guidance for 
additional information regarding fed studies 

______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Azilsartan and chlorthalidone in 
plasma 

 

Bioequivalence based on (90% CI): Azilsartan and chlorthalidone 

 

Waiver request of in vivo testing: Eq 40 mg/12.5 mg, based on (i) acceptable bioequivalence 
studies on the Eq 40 medoxomil mg/25 mg strength, (ii) acceptable in vitro dissolution testing of 
all strengths, and (iii) proportional similarity of the formulations across all strengths 

 

Dissolution test method and sampling times: The dissolution information for this drug product 
can be found on the FDA-Recommended Dissolution Methods website available to the public at 


Recommended Mar 2015 2 
the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct 
comparative dissolution testing on 12 dosage units each of all strengths of the test and reference 
products. Specifications will be determined upon review of the abbreviated new drug application 
(ANDA). 

